Abstract
The dystrophinopathies include a spectrum of muscle disease caused by mutations in the DMD gene that encodes the protein dystrophin. They are characterized by a spectrum of muscle disease that ranges from mild to severe. The mild end of the spectrum includes the phenotypes of asymptomatic increase in serum concentration of creatine phosphokinase (CK) and muscle cramps with myoglobinuria and isolated quadriceps myopathy. The severe end of the spectrum includes progressive muscle diseases that are classified as Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) when skeletal muscle is primarily affected and as X-linked dilated cardiomyopathy (XLDCM) when the heart is primarily affected. In this chapter, I will limit my discussion on DMD and BMD.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Altman DJ, Gilchrist JM: Dystrophinopathies. Emedicine, 2002. http://www.emedicine.com
Beggs AH, Kunkel LM: Improved diagnosis of Duchenne/Becker muscular dystrophy. J Clin Invest 85:613–619, 1990.
Beggs AH, Koenig M, Boyce F, et al.: Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet 86:45–48, 1990.
Biggar WD, Klamut HJ, Demacio PC, et al.: Duchenne muscular dystrophy: Current knowledge, treatment, and future prospects. Clin Orthop Rel Res 401:88–106, 2002.
Brooke MH, Griggs RC, Mendell JR, et al.: The natural history of Duchenne muscular dystrophy (DMD): a caveat for therapeutic trials. Trans Am Neurol Assoc 106:195–199, 1981.
Cox GF, Kunkel LM: Dystrophies and heart disease. Curr Opin Cardiol 12:329–343, 1997.
Eggers S, Pavanello RC, Passos-Bueno MR, et al.: Genetic counseling for childless women at risk for Duchenne muscular dystrophy. Am J Med Genet 86:447–453, 1999.
Emery AH: The muscular dystrophies. Lancet 359:687–695, 2002.
Gillard EF, Chamberlain JS, Murphy EG, et al.: Molecular and phenotype analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene. Am J Hum Genet 45:507–520, 1989.
Heckmatt JZ, Moosa A, Hutson C, et al.: Diagnostic needle muscle biopsy, a practical and reliable alternative to open biopsy. Arch Dis Child 59:528–532, 1984.
Hoffman EP, Brown RH, Jr., Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919–928, 1987.
Hoffman EP, Fischbeck KH, Brown RH, et al.: Characterization of dystrophin in muscle-biopsy specimens from Duchenne’s and Becker’s muscular dystrophy patients. N Enl J Med 318:1363–1368, 1988.
Hoffman EP, Arahata K, Minetti C, et al.: Dystrophinopathy in isolated cases of myopathy in females. Neurology 42:967–975, 1992.
Hu XY, Ray PN, Murphy EG, et al.: Duplicational mutation at the Duchenne muscular dystrophy locus: its frequency, distribution, origin, and phenotype genotype correlation. Am J Hum Genet 46:682–695, 1990.
Jacobs PA, Hunt PA, Mayer M, et al.: Duchenne muscular dystrophy (DMD) in a female with an X/autosome translocation: further evidence that the DMD locus is at Xp21. Am J Hum Genet 33:513–518, 1981.
Kapsa R, Kornberg AJ, Byrne E: Novel therapies for Duchenne muscular dystrophy. Lancet Neurol 2:299–310, 2003.
Koenig M, Hoffman EP, Bertelson CJ, et al.: Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:509–517, 1987.
Koenig M, Beggs AH, Moyer M, et al.: The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45:498–506, 1989.
Korf BR, Darras BT, Urion DK: Dystrophinopathies. Gene Reviews, 2003. http://www.genetests.org
Malhortra SB, Hart KA, Klamut HJM, et al.: Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science 242:755–759, 1988.
Mathews KD: Muscular dystrophy overview: genetics and diagnosis. Neurol Clin 21:795–816, 2003.
Mendell JR, Buzin CH, Feng J, et al.: Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. Neurology 57:645–650, 2001.
Muntoni F, Torelli S, Ferlini A: Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2:731–740, 2003.
Nevo Y, Shomrat R, Yaron Y, et al.: Fetal muscle biopsy as a diagnostic tool in Duchenne muscular dystrophy. Prenat Diagn 19:921–926, 1999.
Perloff JK, Roberts WC, de Leon AC Jr, et al.: The distinctive electrocardiogram of Duchenne’s progressive muscular dystrophy. Am J Med 42:179–188, 1967.
Roest PA, Roberts RG, van der Tuijn AC, et al.: Protein truncation test (PTT) to rapidly screen the DMD gene for translation terminating mutations. Neuromuscul Disord 3:391–394, 1993.
Roland EH: Muscular dystrophy. Pediatr Rev 21:233–237, 2000.
Van Deutekom JC, Van Ommen GJ: Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet 4:774–783, 2003.
Wagner KR: Genetic diseases of muscle. Neurol Clin 20:675–678, 2002.
Worton RG, Thompson MW: Genetics of Duchenne muscular dystrophy. Annu Rev Genet 22:601–629, 1988.
Worton RG, Molnar MJ, Brais B, et al.: The muscular dystrophies. In Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic & Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill, 2001.
Rights and permissions
Copyright information
© 2006 Humana Press Inc.
About this chapter
Cite this chapter
(2006). Dystrophinopathies. In: Atlas of Genetic Diagnosis and Counseling. Humana Press. https://doi.org/10.1007/978-1-60327-161-5_60
Download citation
DOI: https://doi.org/10.1007/978-1-60327-161-5_60
Publisher Name: Humana Press
Print ISBN: 978-1-58829-681-8
Online ISBN: 978-1-60327-161-5
eBook Packages: MedicineMedicine (R0)